Monday, 30th May 2016

google plus twitter

Traders' views - Stock trading

390 articles found

First | 1 | 2 | 3 | 4 | ... | 39 | Last
Graham Spooner

Investment insights of this week May 23rd - 27th

By , 25 May 2016

Graham Spooner, investment research analyst, picks three stocks from last week’s most-bought shares on the London Stock Exchange.

Investment insights highlights this week are: National Grid, Royal Dutch Shell and Lonmin, which all stand out in a good and in a bad way last week.

More...

Nicolas Shamtanis

A quick guide to key announcements

By , 23 May 2016

Each day, governments, central banks and research firms release important economic statistics and reports that help traders evaluate the economy and financial markets.

The financial calendar helps traders anticipate those releases and take positions accordingly. 

More...

Nicolas Shamtanis

Three ways to analyse the markets

By , 19 May 2016

There are many ways to trade and possibly profit in the capital markets. In deploying a trading strategy investors usually undertake some form of analysis to develop a theme in order to execute a successful trade. 

Although the types of analysis used can vary, in general seasoned investors follow some form of fundamental analysis, technical analysis or statistical analysis.

More...

Graham Spooner

Investment insights of this week May 16th - 20th

By , 18 May 2016

Graham Spooner, investment research analyst, picks three stocks from last week’s most-bought shares on the London Stock Exchange.

Investment insights highlights this week are: Vodafone, Aviva and Ferrum Crescent, which all stand out in a good and in a bad way last week.

More...

Graham Spooner

Investment insights of this week May 9th - 13th

By , 11 May 2016

Graham Spooner, investment research analyst, picks three stocks from last week’s most-bought shares on the London Stock Exchange.

Investment insights highlights this week are: Glaxo, Centrica and Tullow Oil, which all stand out in a good and in a bad way last week.

More...

Graham Spooner

Investment insights of this week May 1st - 6th

By , 05 May 2016

Graham Spooner, investment research analyst, picks three stocks from last week’s most-bought shares on the London Stock Exchange.

More...

Nicolas Shamtanis

What we can learn from the three wealthiest traders today

By , 03 May 2016

When we talk of the wealthiest traders in forex, many remember people like George Soros, who made billions from shorting the British Pound in 1992.

However, such intense speculative trading is not the way to go for beginner retail traders. This is why we carefully picked three other relatively obscure traders who have made fortunes trading forex, to see what lessons we could learn from them.

 

More...

Graham Spooner

Investment insights of this week Apr 25th - 29th

By , 28 Apr 2016

Graham Spooner, investment research analyst, picks three stocks from last week’s most-bought shares on the London Stock Exchange.

Investment insights highlights this week are: Vodafone, ITV and 88 Energy, which all stand out in a good and in a bad way last week.

More...

Andrew Hore

AIM investment watchlist: Judges Scientific (JDG)

By , 23 Apr 2016

Scientific instruments supplier Judges Scientific (JDG) has a strong track record of acquiring niche scientific instruments businesses.

There was a blip in 2014 when demand was weak but Judges bounced back last year and it has already made earnings enhancing acquisitions this year. 

 

More...

Graham Spooner

Investment insights of this week Apr 18th - 22th

By , 20 Apr 2016

Graham Spooner, investment research analyst, picks three stocks from last week’s most-bought shares on the London Stock Exchange.

Investment insights highlights this week are: Glaxo, Taylor Wimpey and Keras Resources, which all stand out in a good and in a bad way last week.

 

More...

390 articles found

First | 1 | 2 | 3 | 4 | ... | 39 | Last

City News

Sunday newspaper round-up: AstraZeneca, oil IPOs, M&S, Exova, Tesco

Thu, 1st Jan - * (ShareCast News) - AstraZeneca, the UK's second-biggest drug developer, will this week outline its next big hope in the battle against cancer by unveiling new data on a class of treatments, known as DNA damage response (DDR) medicines, at a conference in Chicago. The drugs work by stopping cancerous cells repairing themselves, in effect by blocking them from attracting the proteins needed to regenerate, as well as proving much less damaging to the body than chemotherapy.

Which trading game would you like to trade with ?